Neuphoria Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $21.1M
- Price
- $3.91
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.01%
- Volume
- 179.8K
About
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Quick stats
Shares outstanding5.4M
Computed float4.7M
Float / shares86.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001191070
Websitehttp://www.neuphoriatx.com
AI Summary
AI-generated1/18
minorneutrallegal litigation
Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC is investigating potential breaches of fiduciary duty by CBIZ, Inc. (CBZ) and other companies regarding proposed M&A transactions.
The release targets CBZ shareholders alongside those of SAFT, NEUP, and TCBK, encouraging them to contact the firm to discuss legal rights.
This is a standard plaintiff-law-firm solicitation and does not constitute a disclosure by the company itself.